Nutrien (NYSE:NTR – Get Free Report) had its price target decreased by equities researchers at Oppenheimer from $60.00 to $58.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 9.24% from the company’s previous close.
Several other research analysts also recently issued reports on NTR. The Goldman Sachs Group initiated coverage on Nutrien in a research note on Thursday, March 13th. They set a “sell” rating and a $53.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and set a $60.00 target price on shares of Nutrien in a research report on Monday, February 24th. Mizuho increased their price target on shares of Nutrien from $52.00 to $55.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. UBS Group cut their price objective on Nutrien from $54.00 to $52.00 and set a “neutral” rating for the company in a research report on Wednesday, April 16th. Finally, Berenberg Bank increased their target price on Nutrien from $54.00 to $59.00 and gave the company a “buy” rating in a report on Tuesday, April 15th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $59.27.
View Our Latest Stock Analysis on NTR
Nutrien Price Performance
Nutrien (NYSE:NTR – Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.09). Nutrien had a return on equity of 6.81% and a net margin of 2.62%. The firm had revenue of $5.08 billion during the quarter, compared to analyst estimates of $5.09 billion. As a group, sell-side analysts anticipate that Nutrien will post 3.72 EPS for the current year.
Institutional Trading of Nutrien
Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Nutrien by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 19,778,500 shares of the company’s stock worth $885,009,000 after purchasing an additional 325,210 shares during the period. Dodge & Cox raised its stake in shares of Nutrien by 0.3% in the 4th quarter. Dodge & Cox now owns 12,523,259 shares of the company’s stock valued at $560,416,000 after acquiring an additional 40,800 shares during the period. Silchester International Investors LLP lifted its holdings in shares of Nutrien by 9.5% during the 4th quarter. Silchester International Investors LLP now owns 11,693,137 shares of the company’s stock valued at $523,268,000 after acquiring an additional 1,009,895 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in Nutrien by 0.8% in the 4th quarter. First Eagle Investment Management LLC now owns 9,529,311 shares of the company’s stock valued at $426,436,000 after purchasing an additional 77,174 shares in the last quarter. Finally, Deutsche Bank AG raised its position in Nutrien by 11.3% in the fourth quarter. Deutsche Bank AG now owns 7,105,057 shares of the company’s stock valued at $317,951,000 after purchasing an additional 721,935 shares during the period. 63.10% of the stock is owned by hedge funds and other institutional investors.
About Nutrien
Nutrien Ltd. provides crop inputs and services. The company operates through four segments: Retail, Potash, Nitrogen, and Phosphate. The Retail segment distributes crop nutrients, crop protection products, seeds, and merchandise products. The Potash segment provides granular and standard potash products.
Further Reading
- Five stocks we like better than Nutrien
- Are Penny Stocks a Good Fit for Your Portfolio?
- 4 Stocks With +3% Yields and 50+ Years of Dividend Increases
- What Are Growth Stocks and Investing in Them
- Medtronic: A Dividend Aristocrat With Stability and Innovation
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
Receive News & Ratings for Nutrien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutrien and related companies with MarketBeat.com's FREE daily email newsletter.